Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 62
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Surpassing protein specificity in biomimetics of bacterial amyloids

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Parladé, Eloi|||0000-0001-5750-550X
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
In nature, nontoxic protein amyloids serve as dynamic, protein-specific depots, exemplified by both bacterial inclusion bodies and secretory granules from the endocrine system. Inspired by these systems, chemically defined and regulatory-compliant artificial protein microgranules have been developed for clinical applications as endocrine-like protein repositories. This has been achieved by exploiting the reversible coordination between histidine residues and divalent cations such as Zn, that promotes protein-protein interactions. While stereospecificity is a main architectonic feature of natural amyloids, the potential for synthetic approaches to create hybrid protein materials remains unexplored. Such materials could enable the occurrence and synchronized local application of diverse proteins in predefined molar ratios, for coupled enzymatic reactions or delivery of synergistically acting polypeptides. Here, we report on the fabrication of artificial protein granules with amyloidal architecture formed by combining two structurally distinct polypeptides. Specifically, we tested co-aggregation of the pairs GFP/IRFP and GFP/β-galactosidase. The formation of hybrid microparticles was confirmed through FRET and complementary methodologies, demonstrating that the His-Zn clustering technology does not require sequential or structural homologies between aggregating polypeptides. This approach opens new avenues for the development of functional depots that capitalize on synergistic protein functionalities, paving the way for next-generation functional materials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Citrate-Assisted Regulation of Protein Stability and Secretability from Synthetic Amyloids

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Chellou-Bakkali, Sara|||0009-0007-1643-4558
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
The mammalian endocrine system uses functional amyloids as dynamic depots to store and release protein hormones into the bloodstream. Such depots, acting as secretory granules within the microscale, are formed in specialized cells by the coordination between the ionic, divalent form of zinc (Zn2+) and the imidazole ring from accessible His residues. The reversibility of such cross-linking events allows for the release of monomeric or oligomeric forms of the functional protein for biological activity. In vitro, and mimicking such a natural coordination process, synthetic amyloidal granules with secretory properties can be fabricated using selected therapeutic proteins as building blocks. Then, these microparticles act as delivery systems for endocrine-like, sustained protein release, with proven applicability in vaccinology, cancer therapy, regenerative medicine, and as antimicrobial agents. While the temporal profile in which the protein is leaked from the material might be highly relevant to clinically oriented applications, the fine control of such parameters remains unclear. We have explored here how the kinetics of protein release can be regulated by intervening in the storage formulation of the granules, through the concentration of citrate not only as a buffer component and protein stabilizer but also as a chelating agent. The citrate-assisted, time-prolonged regulatable release of proteins, in their functional form, opens a spectrum of possibilities to adjust the preparation of synthetic secretory granules to specific clinical needs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Trans-Mediated, Cis-Inhibited Paradoxal Activity of Clostridium perfringens Enterotoxin (c-CPE) in Modulating Epithelial Permeability

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Parladé, Eloi|||0000-0001-5750-550X
  • Di Somma, Angela|||0000-0003-4916-7875
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Villaverde, Antonio|||0000-0002-2615-4521
In the context of transdermal delivery, favoring the drug permeability of epithelia through convenient formulations would open new opportunities for local versus systemic drug delivery, envisaging higher patient comfort and an enhanced therapeutic effect. Ligands of tight junctions are interesting agents that enhance epithelial permeability by relaxing the protein complexes that form them. The C-terminal domain of Clostridium perfringens enterotoxin (c-CPE), which binds claudins, one of the tight junction (TJ) components, has been explored here as a functional domain in modular recombinant proteins, to evaluate its ability to self-promote its paracellular epithelial passage in a Caco-2 cell monolayer model. c-CPE-containing fusion proteins bind cells in the absence of internalization and cytotoxicity and support the passage, in trans, of other fusion proteins devoid of c-CPE. However, c-CPE-carrying proteins fail to cross the epithelia by themselves, probably because their affinity for TJs immobilizes them in the intercellular space. Therefore, while recombinant c-CPE versions have been here confirmed as convenient epithelial-permeabilizing agents, a paradoxical behavior has been observed where this effect is only successful when applied in trans, specifically on entities that lack c-CPE. Then, c-CPE itself inhibits the paracellular mobility of carrier molecules, not being suited as a self-driver (in c-CPE-drug complexes) for drug delivery through epithelia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Subcutaneous administration of an endocrine-mimetic, slow-release protein material reduces the severity of SARS-CoV-2 infection

  • Parladé, Eloi|||0000-0001-5750-550X
  • Tarrés-Freixas, Ferran|||0000-0002-1569-0126
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Márquez-Matínez, Merce
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Cantero, Guillermo|||0000-0003-4200-503X
  • Roca, Núria
  • Pérez, Mónica
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Villaverde, Antonio|||0000-0002-2615-4521
Slow-antigen release vaccination systems aim to replicate the prolonged antigen exposure occurring during natural viral infections, which usually last for days or weeks. We have developed a Zn-assisted, self-organizing protein material at the microscale, inspired by the granular depots for protein hormones, that slowly disassembles into functional building block polypeptides under physiological conditions. This endocrine-like platform acts as a dynamic protein depot for prolonged protein release. Having been validated in oncology, regenerative medicine, and in antimicrobial peptide delivery, it also shows promise for immune stimulation. Here, we evaluate, for the first time, whether such artificial secretory granules incorporating the SARS-CoV-2 Spike Receptor Binding Domain (RBD) can elicit a protective immune response against viral challenge in golden Syrian hamsters. The antigen, formulated as secretory granules, was administered in varying doses via intranasal or subcutaneous routes. While the formulations did not prevent infection, they enhanced viral clearance and mitigated body weight loss, particularly with subcutaneous administration. These effects, through the subcutaneous route, were achieved even in the absence of an adjuvant. Additionally, the granules triggered both antigen-specific humoral immunity and antigen-independent immunomodulatory effects, potentially linked to their amyloid-like structure. These findings demonstrate the dual mechanism of this platform, activating both adaptive and innate immune pathways, and its potential as a versatile, adjuvant-free system for enhancing immune responses against infectious diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Targeted Nanotoxin Inhibits Colorectal Cancer Growth Through Local Tumor Pyroptosis and Eosinophil Infiltration and Degranulation

  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Paez, David|||0000-0002-5596-6588
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Álamo, Patricia|||0000-0003-0510-5701
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ranib
  • Alba Castellón, Lorena|||0000-0003-3449-7820
Background: Colorectal cancer (CRC) has traditionally been treated with genotoxic chemotherapy to activate pro-apoptotic proteins to induce anticancer effects. However, cancer cells develop resistance to apoptosis, which leads to recurrence and poor prognosis. Moreover, this kind of therapy has been shown to be highly toxic to healthy tissues and, therefore, to patients. To overcome this issue, we developed a self-assembly tumor-targeted nanoparticle, T22-DITOX-H6, that incorporates the T22 peptide (a CXCR4 ligand) to selectively target cells overexpressing CXCR4, fused to the catalytic domain of diphtheria toxin, that exhibits a potent cytotoxic effect on these CXCR4+ cancer cells that exhibits potent cytotoxic effects on CXCR4-overexpressing cancer cells through the activation of pyroptosis, an immunogenic type of cell death. Methods: Colorectal CXCR4-expressing tumor cells (CT26-CXCR4+) were implanted subcutaneously into immunocompetent mice to study the effects of T22-DITOX-H6 treatment on tumor growth, cell death and innate immune cell recruitment to the tumor. Results: Here, we demonstrated that the T22-DITOX-H6 nanoparticle selectively activated pyroptosis, an immunogenic cell death that differs from apoptosis, leading to cell death in CXCR4-expressing cells, without affecting the viability of CXCR4-lacking cells. In addition, the nanoparticle administered to tumor-bearing mice induced a local antitumor effect due to the selective activation of pyroptosis in CXCR4+ targeted cancer cells. Biochemical analysis of plasma and histological analysis of non-tumor tissues revealed no differences between the groups. Remarkably, pyroptosis activation stimulates eosinophil infiltration into the tumor microenvironment, an effect recently reported to have an anti-tumorigenic function. Conclusion: These results highlight the dual role of CXCR4-targeted cytotoxic nanoparticle in eliminating cancer cells and boosting the self-immune response without compromising healthy organs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Subcutaneous administration of an endocrine-mimetic platform allows for prolonged tumor uptake of a tumor targeting protein

  • Álamo, Patricia|||0000-0003-0510-5701
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
Endocrine-like dynamic protein depots can be fabricated in vitro through the coordination of divalent zinc ions (Zn) with solvent-exposed histidine residues on functional proteins, leading to their controlled aggregation. The resulting microparticles, under physiological conditions, undergo progressive disintegration due to spontaneous Zn dilution, enabling a time-sustained release of the protein components. These chemically pure protein-based materials represent promising drug delivery platforms, with demonstrated efficacy in oncology, vaccinology, tissue regeneration, and antibacterial therapies. To enable systemic delivery of the embedded protein, alternative administration routes are potentially suited, but their effectiveness in terms of biodistribution and accumulation in target tissues remains unexplored. Using a CXCR4 cancer mouse model, we investigated the tumor targeting and permanence of a self-assembling, CXCR4-binding fluorescent protein administered in the form of secretory granules via subcutaneous, intramuscular, or intraperitoneal injection. Our data reveal that subcutaneous administration supports prolonged protein retention at the injection site, its release within the local draining lymphatic vessels, extended circulation time, and significantly higher tumor accumulation 10 days post-injection. Compared to intramuscular and intraperitoneal routes, the subcutaneous pathway presents clear advantages, potentially allowing reduced dosing frequency in protein-based therapies aimed at maintaining steady systemic and target tissue levels.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Nanotoxin induces in situ pyroptosis to sensitize αPD1 to ablate metastases in microsattellite stable colorectal cancer

  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Otero-Mateo, Marc
  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Paez, David|||0000-0002-5596-6588
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ramon|||0000-0003-2661-9525
Nanomedicine has not generated anticancer immunotherapies because of insufficient targeted specificity, lack of immunity, and associated toxicity. We developed a T22-DITOX-H6 (TDX) nanotoxin to selectively release the diphtheria toxin in the cancer cells in immunosuppressed CXCR4-overexpressing (CXCR4 +) colorectal (CRC) models, inducing pyroptosis and anticancer effect. Microsatellite stable (MSS) CRC patients do not respond to current immunotherapy. Since pyroptosis is highly immunogenic, we treated with TDX immunocompetent CXCR4 + CT26 MSS metastatic CRC models to selectively deliver the toxin to induce in situ pyroptosis mediated by the activation of NLRP3, Caspase-1 GSDMD and IL-1β. In contrast to immunosuppressed, in situ pyroptosis by TDX in immunocompetent models trigger CD8 + T cell recruitment, activation and killing of cancer cells in tissues, mimicking the pyroptosis that the host induces to kill diphtheria-infected cells. The combination of TDX and αPD1 further increases CD8 + recruitment and perforin secretion, achieving a tissue-specific antimetastatic activity in mesentery, peritoneum, and lung, and especially in liver metastases, without systemic toxicity. This is the first time that a novel nanomedicine achieves local T cell activation and antimetastatic effect mediated by pyroptosis and immunogenic cell death, whereas the combination with αPD1 enhances T cell activation, reaching a synergistic response in MSS CRC models.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Nanoparticle-Based Secretory Granules Induce a Specific and Long-Lasting Immune Response through Prolonged Antigen Release

  • Bosch Camós, Laia
  • Martínez-Torró, Carlos
  • López-Laguna, Hèctor
  • Lascorz, Jara
  • Argilaguet, Jordi
  • Villaverde, Antonio
  • Rodriguez, Fernando
  • Vázquez, Esther
Developing prolonged antigen delivery systems that mimic long-term exposure to pathogens appears as a promising but still poorly explored approach to reach durable immunities. In this study, we have used a simple technology by which His-tagged proteins can be assembled, assisted by divalent cations, as supramolecular complexes with progressive complexity, namely protein-only nanoparticles and microparticles. Microparticles produced out of nanoparticles are biomimetics of secretory granules from the mammalian hormonal system. Upon subcutaneous administration, they slowly disintegrate, acting as an endocrine-like secretory system and rendering the building block nanoparticles progressively bioavailable. The performance of such materials, previously validated for drug delivery in oncology, has been tested here regarding the potential for time-prolonged antigen release. This has been completed by taking, as a building block, a nanostructured version of p30, a main structural immunogen from the African swine fever virus (ASFV). By challenging the system in both mice and pigs, we have observed unusually potent pro-inflammatory activity in porcine macrophages, and long-lasting humoral and cellular responses in vivo, which might overcome the need for an adjuvant. The robustness of both innate and adaptive responses tag, for the first time, these dynamic depot materials as a novel and valuable instrument with transversal applicability in immune stimulation and vaccinology., This project was mainly funded by the proof-of-concept project NANOSWINE, granted by UAB-Generalitat de Catalunya to E.V. and A.V. The authors are indebted to the Agencia Española de Investigación (AEI) for granting projects on the construction of protein materials of clinical interest (PID2019-105416RB-I00/AEI/10.13039/501100011033 and PDC2022-133858-I00 to E.V. and PID2020-116174RB-I00 to A.V.), to AGAUR for project SGR 2021 00092 to A.V., and to the Spanish Ministry of Science and Innovation (grant reference PID2022-136312OB-I00 to FR). C.M.-T. was supported by a Margarita Salas grant from Universitat Autònoma de Barcelona and Ministerio de Universidades (funded by the European Union—NextGenerationEU). We also appreciate the support from CIBER—Consorcio Centro de Investigación Biomédica en Red (CB06/01/0014), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and Red de Investigación en Sanidad Animal (RISA). A.V. received an ICREA ACADEMIA award. The production of the therapeutic proteins was assisted, in part, by the Protein Production (PPP) Unit of the ICTS Nanbiosis Platform of the CIBER-BBN/IBB (http://www.nanbiosis. es/unit/u1-protein-production-platform-ppp/, accessed on 28 January 2024)., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Subcutaneous administration of an endocrine-mimetic, slow-release protein material reduces the severity of SARS-CoV-2 infection

  • Parladé, Eloi
  • Tarrés Freixas, Ferran
  • Favaro, Marianna T.P.
  • Lascorz, Jara
  • Marquez-Matínez, Merce
  • Mendoza, Rosa
  • Corchero, José Luís
  • Cantero Portillo, Guillermo
  • Roca, Núria
  • Pérez, Mónica
  • Ferrer-Miralles, Neus
  • Vazquez, Esther
  • Segalés, Joaquim
  • Vergara-Alert, Júlia
  • Villaverde, Antonio
Slow-antigen release vaccination systems aim to replicate the prolonged antigen exposure occurring during natural viral infections, which usually last for days or weeks. We have developed a Zn-assisted, self-organizing protein material at the microscale, inspired by the granular depots for protein hormones, that slowly disassembles into functional building block polypeptides under physiological conditions. This endocrine-like platform acts as a dynamic protein depot for prolonged protein release. Having been validated in oncology, regenerative medicine, and in antimicrobial peptide delivery, it also shows promise for immune stimulation. Here, we evaluate, for the first time, whether such artificial secretory granules incorporating the SARS-CoV-2 Spike Receptor Binding Domain (RBD) can elicit a protective immune response against viral challenge in golden Syrian hamsters. The antigen, formulated as secretory granules, was administered in varying doses via intranasal or subcutaneous routes. While the formulations did not prevent infection, they enhanced viral clearance and mitigated body weight loss, particularly with subcutaneous administration. These effects, through the subcutaneous route, were achieved even in the absence of an adjuvant. Additionally, the granules triggered both antigen-specific humoral immunity and antigen-independent immunomodulatory effects, potentially linked to their amyloid-like structure. These findings demonstrate the dual mechanism of this platform, activating both adaptive and innate immune pathways, and its potential as a versatile, adjuvant-free system for enhancing immune responses against infectious diseases., The project was mainly funded by AGAUR (grant number 2020PANDE00003) and CIBER-Consorcio Centro de Investigación Biomédica en Red- (grant number CB06/01/0014), through the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, within the intramural project NANOSARS (to E.P.). We also gratefully acknowledge the support from AEI for the development of multimeric recombinant drugs (grant numbers PID2019-105416RB-I00/AEI/10.13039/501100011033 and PDC2022-133858-I00 to E.V., PID2019-107298RB-C22/AEI/10.13039/501100011033 to N.F.-M., PID2020-116174RB-I00 to A.V. and PID2022-1368450 OB-10/AEI/10.13039/501100011033 to A.V. and E.V.). Our team also received support from AGAUR for our activities in drug design (grant number 2021SGR00092 to A.V.). Protein production was partially performed by the ICTS “NANBIOSIS”, more specifically by the Protein Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN)/IBB, at the UAB (http://www.nanbiosis.es/portfolio/u1-protein-production-platform-ppp). IRTA is supported by CERCA Programme/Generalitat de Catalunya. The authors also acknowledge the invaluable assistance of the animal caretakers at the BSL3 facility at IRTA., info:eu-repo/semantics/publishedVersion
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Lyophilization of biomimetic amyloids preserves their regulatable, endocrine- like functions for nanoparticle release

  • Teixeira De Pinho Favaro, Marianna
  • Lopez Laguna, Hector
  • Voltà Durán, Eric|||0000-0003-0017-8274
  • Alba Castellon, Lorena
  • Sánchez Quiroga, Julieta María
  • Casanova Rigat, Isolda
  • Unzueta Elorza, Ugutz
  • Mangues, Ramón
  • Villaverde Corrales, Antonio
  • Vázquez Gómez, Esther
The secretory granules from the mammalian endocrine system are functional amyloids that act as dynamic depots to store and release protein hormones into the bloodstream. The controlled in vitro coordination between divalent cations and solvent-exposed histidine residues triggers reversible, cross-molecular interactions that result in granular protein aggregates with protein-leaking properties. While these synthetic particles are mechanically stable, they progressively disintegrate and release their protein building blocks, mimicking the performance of secretory granules. Envisaged as delivery systems for endocrine-like, time-sustained protein release, their clinical applicability should be supported by robust storage procedures, so far unset. Being lyophilization a desirable storage method for protein drugs, how this procedure could preserve the performance of clinically oriented functional amyloids is a neglected issue. We have here explored, tailored and validated lyophilization as an industrially and clinically friendly, fully scalable approach to the storage of functional amyloids aimed at secretion of protein-only nanoparticles. By doing so, protein-protein interactions in such materials have been characterized, and citrate identified as an efficient modulator of the temporal secretion profile, through which the sustainability of the leaking process can be finely regulated., We appreciate the support from AEI (Spain) for the development of multimeric recombinant drugs (PID2019–105416RB-I00/AEI/ 10.13039/501100011033 and PDC2022–133858-I00 to E.V., and PID2022–1368450 OB-10/AEI/10.13039/501100011033 to AV and EV) and to Instituto de Salud Carlos III (PI20/00400 and PI23/00318 to U.U., and PI21/00150 to R.M.) co-funded by European Regional Development Fund (ERDF, a way to make Europe). JMS is supported with a María Zambrano postdoctoral researcher contract (677904) from Ministerio de Universidades and European Union (“Financed by European Union-Next GenerationEU”).The authors also appreciate the financial support received from AGAUR (2021SGR00092 to A.V. and 2021SGR01140 to R.M), from CIBER -Consorcio Centro de Investigacion´ Biomédica en Red- (CB06/01/0014 and CB06/01/1031), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion, ´ through intramural projects (NANO4CANCER to A.V.,NANOREMOTE to E.V. and 4NANOMETS to R.M.). U.U. is supported by Miguel Servet contract (CP19/ 00028) from ISCIII co-funded by European Social Fund (ESF investing in your future), L. A-C is supported by AECC (Spain) Postdoctoral fellowship (POSTD20070ALBA). We also acknowledge the support from Microscopy Service, the Proteomics and Structural Biology Service and the Cell Culture, Antibody Production and Cytometry Service, all in the UAB. Protein production was partially performed by the ICTS “NANBIOSIS”, more specifically by the Protein Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN)/ IBB, at the UAB (http://www.nanbiosis.es/portfolio/u1-protein-productio n-platform-ppp/)., Peer Reviewed, 3 - Salut i Benestar, 9 - Indústria, Innovació i Infraestructura
UPCommons. Portal del coneixement obert de la UPC
Publicación Artículo científico (JournalArticle)

Hybrid micro-/nanoprotein platform provides endocrine-like and extracellular matrix-like cell delivery of growth factors

  • Lopez Laguna, Hector
  • Tsimbouri, Penelope M.
  • Jayawarna, Vineetha
  • Rigou, Ioanna
  • Serna, Naroa
  • Voltà Durán, Eric|||0000-0003-0017-8274
  • Unzueta Elorza, Ugutz
  • Salmerón Sánchez, Manuel
  • Vázquez Gómez, Esther
  • Dalby, Matthew J.
  • Villaverde Corrales, Antonio
Protein materials are versatile tools in diverse biomedical fields. Among them, artificial secretory granules (SGs), mimicking those from the endocrine system, act as mechanically stable reservoirs for the sustained release of proteins as oligomeric functional nanoparticles. Only validated in oncology, the physicochemical properties of SGs, along with their combined drug-releasing and scaffolding abilities, make them suitable as smart topographies in regenerative medicine for the prolonged delivery of growth factors (GFs). Thus, considering the need for novel, safe, and cost-effective materials to present GFs, in this study, we aimed to biofabricate a protein platform combining both endocrine-like and extracellular matrix fibronectin-derived (ECM-FN) systems. This approach is based on the sustained delivery of a nanostructured histidine-tagged version of human fibroblast growth factor 2. The GF is presented onto polymeric surfaces, interacting with FN to spontaneously generate nanonetworks that absorb and present the GF in the solid state, to modulate mesenchymal stromal cell (MSC) behavior. The results show that SGs-based topographies trigger high rates of MSCs proliferation while preventing differentiation. While this could be useful in cell therapy manufacture demanding large numbers of unspecialized MSCs, it fully validates the hybrid platform as a convenient setup for the design of biologically active hybrid surfaces and in tissue engineering for the controlled manipulation of mammalian cell growth., The study was mainly funded by the Agencia Española de Investigacioń (AEI) through the project PID2020-116174RBI00 granted to A.V. The authors are indebted to AEI for granting additional projects on the construction of protein materials of clinical interest (PID2019-105416RB-I00/AEI/10.13039/ 501100011033 and PDC2022-133858-I00 to E.V., PID2022- 1368450 OB-10/AEI/10.13039/501100011033 to A.V. and E.V.), to AGAUR (SGR 2021 00092 to A.V.), and to ISCIII (PI20/00400 and PI23/00318 to UU) co-funded by European Regional Development Fund (ERDF, a way to make Europe). U.U. was supported by the Miguel Servet contract (CP19/ 00028) from ISCIII, co-funded by the European Social Fund (ESF investing in your future). A.V. received an ICREA ACADEMIA award. M.J.D. is also indebted to the EPSRC grant (EP/P001114/1). We would like to thank ISCIII for funding through CIBER-BBN (CB06/01/0014) and the Ministry of Science for funding the ICTS Platform Nanbiosis. H.L.-L. received a predoctoral fellowship from AGAUR (2019 FI_B 00352)., Peer Reviewed, 3 - Salut i Benestar, 9 - Indústria, Innovació i Infraestructura
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Hybrid micro-/nanoprotein platform provides endocrine-like and extracellular matrix-like cell delivery of growth factors

  • Lopez Laguna, Hector
  • Tsimbouri, Penelope M.
  • Jayawarna, Vineetha
  • Rigou, Ioanna
  • Serna, Naroa
  • Voltà Durán, Eric
  • Unzueta Elorza, Ugutz
  • Salmerón Sánchez, Manuel
  • Vázquez Gómez, Esther
  • Dalby, Matthew J.
  • Villaverde Corrales, Antonio
Protein materials are versatile tools in diverse biomedical fields. Among them, artificial secretory granules (SGs), mimicking those from the endocrine system, act as mechanically stable reservoirs for the sustained release of proteins as oligomeric functional nanoparticles. Only validated in oncology, the physicochemical properties of SGs, along with their combined drug-releasing and scaffolding abilities, make them suitable as smart topographies in regenerative medicine for the prolonged delivery of growth factors (GFs). Thus, considering the need for novel, safe, and cost-effective materials to present GFs, in this study, we aimed to biofabricate a protein platform combining both endocrine-like and extracellular matrix fibronectin-derived (ECM-FN) systems. This approach is based on the sustained delivery of a nanostructured histidine-tagged version of human fibroblast growth factor 2. The GF is presented onto polymeric surfaces, interacting with FN to spontaneously generate nanonetworks that absorb and present the GF in the solid state, to modulate mesenchymal stromal cell (MSC) behavior. The results show that SGs-based topographies trigger high rates of MSCs proliferation while preventing differentiation. While this could be useful in cell therapy manufacture demanding large numbers of unspecialized MSCs, it fully validates the hybrid platform as a convenient setup for the design of biologically active hybrid surfaces and in tissue engineering for the controlled manipulation of mammalian cell growth., The study was mainly funded by the Agencia Española de Investigacioń (AEI) through the project PID2020-116174RBI00 granted to A.V. The authors are indebted to AEI for granting additional projects on the construction of protein materials of clinical interest (PID2019-105416RB-I00/AEI/10.13039/ 501100011033 and PDC2022-133858-I00 to E.V., PID2022- 1368450 OB-10/AEI/10.13039/501100011033 to A.V. and E.V.), to AGAUR (SGR 2021 00092 to A.V.), and to ISCIII (PI20/00400 and PI23/00318 to UU) co-funded by European Regional Development Fund (ERDF, a way to make Europe). U.U. was supported by the Miguel Servet contract (CP19/ 00028) from ISCIII, co-funded by the European Social Fund (ESF investing in your future). A.V. received an ICREA ACADEMIA award. M.J.D. is also indebted to the EPSRC grant (EP/P001114/1). We would like to thank ISCIII for funding through CIBER-BBN (CB06/01/0014) and the Ministry of Science for funding the ICTS Platform Nanbiosis. H.L.-L. received a predoctoral fellowship from AGAUR (2019 FI_B 00352)., Peer Reviewed, 3 - Salut i Benestar, 9 - Indústria, Innovació i Infraestructura, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Subcutaneous administration of an endocrine-mimetic, slow-release protein material reduces the severity of SARS-CoV-2 infection

  • Parladé, Eloi
  • Tarrés Freixas, Ferran
  • Favaro, Marianna T.P.
  • Lascorz, Jara
  • Marquez-Matínez, Merce
  • Mendoza, Rosa
  • Corchero, José Luís
  • Cantero Portillo, Guillermo
  • Roca, Núria
  • Pérez, Mónica
  • Ferrer-Miralles, Neus
  • Vazquez, Esther
  • Segalés, Joaquim
  • Vergara-Alert, Júlia
  • Villaverde, Antonio
Slow-antigen release vaccination systems aim to replicate the prolonged antigen exposure occurring during natural viral infections, which usually last for days or weeks. We have developed a Zn-assisted, self-organizing protein material at the microscale, inspired by the granular depots for protein hormones, that slowly disassembles into functional building block polypeptides under physiological conditions. This endocrine-like platform acts as a dynamic protein depot for prolonged protein release. Having been validated in oncology, regenerative medicine, and in antimicrobial peptide delivery, it also shows promise for immune stimulation. Here, we evaluate, for the first time, whether such artificial secretory granules incorporating the SARS-CoV-2 Spike Receptor Binding Domain (RBD) can elicit a protective immune response against viral challenge in golden Syrian hamsters. The antigen, formulated as secretory granules, was administered in varying doses via intranasal or subcutaneous routes. While the formulations did not prevent infection, they enhanced viral clearance and mitigated body weight loss, particularly with subcutaneous administration. These effects, through the subcutaneous route, were achieved even in the absence of an adjuvant. Additionally, the granules triggered both antigen-specific humoral immunity and antigen-independent immunomodulatory effects, potentially linked to their amyloid-like structure. These findings demonstrate the dual mechanism of this platform, activating both adaptive and innate immune pathways, and its potential as a versatile, adjuvant-free system for enhancing immune responses against infectious diseases., The project was mainly funded by AGAUR (grant number 2020PANDE00003) and CIBER-Consorcio Centro de Investigación Biomédica en Red- (grant number CB06/01/0014), through the Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, within the intramural project NANOSARS (to E.P.). We also gratefully acknowledge the support from AEI for the development of multimeric recombinant drugs (grant numbers PID2019-105416RB-I00/AEI/10.13039/501100011033 and PDC2022-133858-I00 to E.V., PID2019-107298RB-C22/AEI/10.13039/501100011033 to N.F.-M., PID2020-116174RB-I00 to A.V. and PID2022-1368450 OB-10/AEI/10.13039/501100011033 to A.V. and E.V.). Our team also received support from AGAUR for our activities in drug design (grant number 2021SGR00092 to A.V.). Protein production was partially performed by the ICTS “NANBIOSIS”, more specifically by the Protein Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN)/IBB, at the UAB (http://www.nanbiosis.es/portfolio/u1-protein-production-platform-ppp). IRTA is supported by CERCA Programme/Generalitat de Catalunya. The authors also acknowledge the invaluable assistance of the animal caretakers at the BSL3 facility at IRTA., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Lyophilization of biomimetic amyloids preserves their regulatable, endocrine- like functions for nanoparticle release

  • Teixeira De Pinho Favaro, Marianna
  • Lopez Laguna, Hector
  • Voltà Durán, Eric
  • Alba Castellon, Lorena
  • Sánchez Quiroga, Julieta María
  • Casanova Rigat, Isolda
  • Unzueta Elorza, Ugutz
  • Mangues, Ramón
  • Villaverde Corrales, Antonio
  • Vázquez Gómez, Esther
The secretory granules from the mammalian endocrine system are functional amyloids that act as dynamic depots to store and release protein hormones into the bloodstream. The controlled in vitro coordination between divalent cations and solvent-exposed histidine residues triggers reversible, cross-molecular interactions that result in granular protein aggregates with protein-leaking properties. While these synthetic particles are mechanically stable, they progressively disintegrate and release their protein building blocks, mimicking the performance of secretory granules. Envisaged as delivery systems for endocrine-like, time-sustained protein release, their clinical applicability should be supported by robust storage procedures, so far unset. Being lyophilization a desirable storage method for protein drugs, how this procedure could preserve the performance of clinically oriented functional amyloids is a neglected issue. We have here explored, tailored and validated lyophilization as an industrially and clinically friendly, fully scalable approach to the storage of functional amyloids aimed at secretion of protein-only nanoparticles. By doing so, protein-protein interactions in such materials have been characterized, and citrate identified as an efficient modulator of the temporal secretion profile, through which the sustainability of the leaking process can be finely regulated., We appreciate the support from AEI (Spain) for the development of multimeric recombinant drugs (PID2019–105416RB-I00/AEI/ 10.13039/501100011033 and PDC2022–133858-I00 to E.V., and PID2022–1368450 OB-10/AEI/10.13039/501100011033 to AV and EV) and to Instituto de Salud Carlos III (PI20/00400 and PI23/00318 to U.U., and PI21/00150 to R.M.) co-funded by European Regional Development Fund (ERDF, a way to make Europe). JMS is supported with a María Zambrano postdoctoral researcher contract (677904) from Ministerio de Universidades and European Union (“Financed by European Union-Next GenerationEU”).The authors also appreciate the financial support received from AGAUR (2021SGR00092 to A.V. and 2021SGR01140 to R.M), from CIBER -Consorcio Centro de Investigacion´ Biomédica en Red- (CB06/01/0014 and CB06/01/1031), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion, ´ through intramural projects (NANO4CANCER to A.V.,NANOREMOTE to E.V. and 4NANOMETS to R.M.). U.U. is supported by Miguel Servet contract (CP19/ 00028) from ISCIII co-funded by European Social Fund (ESF investing in your future), L. A-C is supported by AECC (Spain) Postdoctoral fellowship (POSTD20070ALBA). We also acknowledge the support from Microscopy Service, the Proteomics and Structural Biology Service and the Cell Culture, Antibody Production and Cytometry Service, all in the UAB. Protein production was partially performed by the ICTS “NANBIOSIS”, more specifically by the Protein Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN)/ IBB, at the UAB (http://www.nanbiosis.es/portfolio/u1-protein-productio n-platform-ppp/)., Peer Reviewed, 3 - Salut i Benestar, 9 - Indústria, Innovació i Infraestructura, Postprint (published version)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Nanoparticle-Based Secretory Granules Induce a Specific and Long-Lasting Immune Response through Prolonged Antigen Release

  • Bosch Camós, Laia
  • Martínez-Torró, Carlos
  • López-Laguna, Hèctor
  • Lascorz, Jara
  • Argilaguet, Jordi
  • Villaverde, Antonio
  • Rodriguez, Fernando
  • Vázquez, Esther
Developing prolonged antigen delivery systems that mimic long-term exposure to pathogens appears as a promising but still poorly explored approach to reach durable immunities. In this study, we have used a simple technology by which His-tagged proteins can be assembled, assisted by divalent cations, as supramolecular complexes with progressive complexity, namely protein-only nanoparticles and microparticles. Microparticles produced out of nanoparticles are biomimetics of secretory granules from the mammalian hormonal system. Upon subcutaneous administration, they slowly disintegrate, acting as an endocrine-like secretory system and rendering the building block nanoparticles progressively bioavailable. The performance of such materials, previously validated for drug delivery in oncology, has been tested here regarding the potential for time-prolonged antigen release. This has been completed by taking, as a building block, a nanostructured version of p30, a main structural immunogen from the African swine fever virus (ASFV). By challenging the system in both mice and pigs, we have observed unusually potent pro-inflammatory activity in porcine macrophages, and long-lasting humoral and cellular responses in vivo, which might overcome the need for an adjuvant. The robustness of both innate and adaptive responses tag, for the first time, these dynamic depot materials as a novel and valuable instrument with transversal applicability in immune stimulation and vaccinology., This project was mainly funded by the proof-of-concept project NANOSWINE, granted by UAB-Generalitat de Catalunya to E.V. and A.V. The authors are indebted to the Agencia Española de Investigación (AEI) for granting projects on the construction of protein materials of clinical interest (PID2019-105416RB-I00/AEI/10.13039/501100011033 and PDC2022-133858-I00 to E.V. and PID2020-116174RB-I00 to A.V.), to AGAUR for project SGR 2021 00092 to A.V., and to the Spanish Ministry of Science and Innovation (grant reference PID2022-136312OB-I00 to FR). C.M.-T. was supported by a Margarita Salas grant from Universitat Autònoma de Barcelona and Ministerio de Universidades (funded by the European Union—NextGenerationEU). We also appreciate the support from CIBER—Consorcio Centro de Investigación Biomédica en Red (CB06/01/0014), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, and Red de Investigación en Sanidad Animal (RISA). A.V. received an ICREA ACADEMIA award. The production of the therapeutic proteins was assisted, in part, by the Protein Production (PPP) Unit of the ICTS Nanbiosis Platform of the CIBER-BBN/IBB (http://www.nanbiosis. es/unit/u1-protein-production-platform-ppp/, accessed on 28 January 2024)., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fluorescent dye labeling changes the biodistribution of cell-targeted nanoparticles

  • Álamo, Patricia|||0000-0003-0510-5701
  • Pallarès, Victor|||0000-0002-9851-0345
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Morris, Gordon A.|||0000-0003-2588-6349
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Fluorescent dye labeling is a common strategy to analyze the fate of administered nanoparticles in living organisms. However, to which extent the labeling processes can alter the original nanoparticle biodistribution has been so far neglected. In this work, two widely used fluorescent dye molecules, namely, ATTO488 (ATTO) and Sulfo-Cy5 (S-Cy5), have been covalently attached to a well-characterized CXCR4-targeted self-assembling protein nanoparticle (known as T22-GFP-H6). The biodistribution of labeled T22-GFP-H6-ATTO and T22-GFP-H6-S-Cy5 nanoparticles has been then compared to that of the non-labeled nanoparticle in different CXCR4+ tumor mouse models. We observed that while parental T22-GFP-H6 nanoparticles accumulated mostly and specifically in CXCR4+ tumor cells, labeled T22-GFP-H6-ATTO and T22-GFP-H6-S-Cy5 nanoparticles showed a dramatic change in the biodistribution pattern, accumulating in non-target organs such as liver or kidney while reducing tumor targeting capacity. Therefore, the use of such labeling molecules should be avoided in target and non-target tissue uptake studies during the design and development of targeted nanoscale drug delivery systems, since their effect over the fate of the nanomaterial can lead to considerable miss-interpretations of the actual nanoparticle biodistribution.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Aviñó, Ana|||0000-0003-3047-738X
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
  • Eritja, Ramon|||0000-0001-5383-9334
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
The possibility to conjugate tumor-targeted cytotoxic nanoparticles and conventional antitumoral drugs in single pharmacological entities would open a wide spectrum of opportunities in nanomedical oncology. This principle has been explored here by using CXCR4-targeted self-assembling protein nanoparticles based on two potent microbial toxins, the exotoxin A from Pseudomonas aeruginosa and the diphtheria toxin from Corynebacterium diphtheriae, to which oligo-floxuridine and monomethyl auristatin E respectively have been chemically coupled. The resulting multifunctional hybrid nanoconjugates, with a hydrodynamic size of around 50 nm, are stable and internalize target cells with a biological impact. Although the chemical conjugation minimizes the cytotoxic activity of the protein partner in the complexes, the concept of drug combination proposed here is fully feasible and highly promising when considering multiple drug treatments aimed to higher effectiveness or when facing the therapy of cancers with acquired resistance to classical drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Blocking intruders, inducible physico-chemical barriers against plant vascular wilt pathogens

  • Kashyap, Anurag|||0000-0003-2622-8209
  • Planas-Marquès, Marc|||0000-0001-7295-7301
  • Capellades, Montserrat|||0000-0001-9514-2885
  • Valls, Marc|||0000-0003-2312-0091
  • Sánchez Coll, Núria|||0000-0002-8889-0399
Xylem vascular wilt pathogens cause devastating diseases in plants. Proliferation of these pathogens in the xylem causes massive disruption of water and mineral transport, resulting in severe wilting and death of the infected plants. Upon reaching the xylem vascular tissue, these pathogens multiply profusely, spreading vertically within the xylem sap, and horizontally between vessels and to the surrounding tissues. Plant resistance to these pathogens is very complex. One of the most effective defense responses in resistant plants is the formation of physico-chemical barriers in the xylem tissue. Vertical spread within the vessel lumen is restricted by structural barriers, namely, tyloses and gels. Horizontal spread to the apoplast and surrounding healthy vessels and tissues is prevented by vascular coating of the colonized vessels with lignin and suberin. Both vertical and horizontal barriers compartmentalize the pathogen at the infection site and contribute to their elimination. Induction of these defenses are tightly coordinated, both temporally and spatially, to avoid detrimental consequences such as cavitation and embolism. We discuss current knowledge on mechanisms underlying plant-inducible structural barriers against major xylem-colonizing pathogens. This knowledge may be applied to engineer metabolic pathways of vascular coating compounds in specific cells, to produce plants resistant towards xylem colonizers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A genome-wide association study reveals cytokinin as a major component in the root defense responses against Ralstonia solanacearum

  • Alonso-Díaz, Alejandro|||0000-0002-7819-3848
  • Satbhai, Santosh B.|||0000-0002-2770-656X
  • de Pedro Jové, Roger|||0000-0002-7083-7960
  • Berry, Hannah M.
  • Göschl, Christian
  • Argueso, Cristiana T.|||0000-0001-7097-9304
  • Novak, Ondrej
  • Busch, Wolfgang|||0000-0003-2042-7290
  • Valls, Marc|||0000-0003-2312-0091
  • Sánchez Coll, Núria|||0000-0002-8889-0399
Bacterial wilt caused by the soil-borne pathogen Ralstonia solancearum is economically devastating, with no effective methods to fight the disease. This pathogen invades plants through their roots and colonizes their xylem, clogging the vasculature and causing rapid wilting. Key to preventing colonization are the early defense responses triggered in the host's root upon infection, which remain mostly unknown. Here, we have taken advantage of a high-throughput in vitro infection system to screen natural variability associated with the root growth inhibition phenotype caused by R. solanacearum in Arabidopsis during the first hours of infection. To analyze the genetic determinants of this trait, we have performed a genome-wide association study, identifying allelic variation at several loci related to cytokinin metabolism, including genes responsible for biosynthesis and degradation of cytokinin. Further, our data clearly demonstrate that cytokinin signaling is induced early during the infection process and cytokinin contributes to immunity against R. solanacearum. This study highlights a new role for cytokinin in root immunity, paving the way for future research that will help in understanding the mechanisms underpinning root defenses.
Dipòsit Digital de Documents de la UAB
Datos de investigación Set de datos (Dataset)

Analysis of EPI-X4 binding to CXCR4, raw data to be linked to a scientific publication

  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Álamo, Patricia|||0000-0003-0510-5701
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Serna, Naroa|||0000-0001-5682-8198
  • Parladé, Eloi|||0000-0001-5750-550X
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Roldán, Mònica
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
This data set contains several Excel files with raw data from a complex set of experiments aiming at exploring the interactivity of EPI-X4 and CXCR4+ cells. Only numerical data from those experimental is included here.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biparatopic protein nanoparticles for the precision therapy of cxcr4+ cancers

  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Álamo, Patricia|||0000-0003-0510-5701
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Serna, Naroa|||0000-0001-5682-8198
  • Parladé, Eloi|||0000-0001-5750-550X
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Roldán, Mònica
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
The accumulated molecular knowledge about human cancer enables the identification of multiple cell surface markers as highly specific therapeutic targets. A proper tumor targeting could significantly avoid drug exposure of healthy cells, minimizing side effects, but it is also expected to increase the therapeutic index. Specifically, colorectal cancer has a particularly poor prognosis in late stages, being drug targeting an appropriate strategy to substantially improve the therapeutic efficacy. In this study, we have explored the potential of the human albumin-derived peptide, EPI-X4, as a suitable ligand to target colorectal cancer via the cell surface protein CXCR4, a chemokine receptor overexpressed in cancer stem cells. To explore the potential use of this ligand, self-assem-bling protein nanoparticles have been generated displaying an engineered EPI-X4 version, which conferred a modest CXCR4 targeting and fast and high level of cell apoptosis in tumor CXCR4 cells, in vitro and in vivo. In addition, when EPI-X4-based building blocks are combined with biologically inert polypeptides containing the CXCR4 ligand T22, the resulting biparatopic nanoparticles show a dramatically improved biodistribution in mouse models of CXCR4 human cancer, faster cell internalization and enhanced target cell death when compared to the version based on a single ligand. The generation of biparatopic materials opens exciting possibilities in oncotherapies based on high precision drug delivery based on the receptor CXCR4.
Dipòsit Digital de Documents de la UAB
Datos de investigación Set de datos (Dataset)

Raw data to support the manuscript "The spectrum of building block conformers sustains the biophysical properties of clinically-oriented, self-assembling protein nanoparticles"

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • de Marco, Ario|||0000-0001-7729-819X
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Raw data of a set of experiments aimed to explore the impact of protein conformation on the structural variability of resulting self-assembling materials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Insights on the emerging biotechnology of histidine-rich peptides

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Parladé, Eloi|||0000-0001-5750-550X
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
In the late 70's, the discovery of the restriction enzymes made possible the biological production of functional proteins by recombinant DNA technologies, a fact that largely empowered both biotechnological and pharmaceutical industries. Short peptides or small protein domains, with specific molecular affinities, were developed as purification tags in downstream processes to separate the target protein from the culture media or cell debris, upon breaking the producing cells. Among these tags, and by exploiting the interactivity of the imidazole ring of histidine residues, the hexahistidine peptide (H6) became a gold standard. Although initially used almost exclusively in protein production, H6 and related His-rich peptides are progressively proving a broad applicability in novel utilities including enzymatic processes, advanced drug delivery systems and diagnosis, through a so far unsuspected adaptation of their binding capabilities. In this context, the coordination of histidine residues and metals confers intriguing functionalities to His-rich sequences useable in the forward-thinking design of protein-based nano- and micro-materials and devices, through strategies that are comprehensively presented here.
Dipòsit Digital de Documents de la UAB
Datos de investigación Set de datos (Dataset)

Dataset for the following MS with provisional title, Ion-dependent slow protein release from in vivo disintegrating micro-granules

  • Álamo, Patricia|||0000-0003-0510-5701
  • Parladé, Eloi|||0000-0001-5750-550X
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
Set DATASET that accompains the manuscript by Alamo and co-workers provisionally entitled Ion-dependent slow protein release from in vivo disintegrating micro-granules.
Dipòsit Digital de Documents de la UAB
Datos de investigación Set de datos (Dataset)

Raw data to support the manuscript with the following intended title, The poly-histidine tag H6 mediates structural and functional properties of disintegrating bacterial amyloids

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Serna, Naroa|||0000-0001-5682-8198
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Nolan, Verónica
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Raw data of a set of experiments aimed to explore the involvement of His-tags in the formation of bacterial inclusion bodies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biofabrication of functional protein nanoparticles through simple His-tag engineering

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Rojas Peña, Mauricio|||0000-0002-2373-1792
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Serna, Naroa|||0000-0001-5682-8198
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Flores, Sandra
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Nolan, Verónica
  • de Marco, Ario|||0000-0001-7729-819X
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
We have developed a simple, robust, and fully transversal approach for thea-la-cartefabrication of functional multimeric nanoparticles with potential biomedical applications, validated here by a set of diverse and unrelated polypeptides. The proposed concept is based on the controlled coordination between Znions and His residues in His-tagged proteins. This approach results in a spontaneous and reproducible protein assembly as nanoscale oligomers that keep the original functionalities of the protein building blocks. The assembly of these materials is not linked to particular polypeptide features, and it is based on an environmentally friendly and sustainable approach. The resulting nanoparticles, with dimensions ranging between 10 and 15 nm, are regular in size, are architecturally stable, are fully functional, and serve as intermediates in a more complex assembly process, resulting in the formation of microscale protein materials. Since most of the recombinant proteins produced by biochemical and biotechnological industries and intended for biomedical research are His-tagged, the green biofabrication procedure proposed here can be straightforwardly applied to a huge spectrum of protein species for their conversion into their respective nanostructured formats.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • de Marco, Ario|||0000-0001-7729-819X
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
Histidine-rich peptides confer self-assembling properties to recombinant proteins through the supramolecular coordination with divalent cations. This fact allows the cost-effective, large-scale generation of microscopic and macroscopic protein materials with intriguing biomedical properties. Among such materials, resulting from the simple bioproduction of protein building blocks, homomeric nanoparticles are of special value as multivalent interactors and drug carriers. Interestingly, we have here identified that the assembly of a given His-tagged protein might render distinguishable categories of self-assembling protein nanoparticles. This fact has been scrutinized through the nanobody-containing fusion proteins EM1-GFP-H6 and A3C8-GFP-H6, whose biosynthesis results in two distinguishable populations of building blocks. In one of them, the assembling and disassembling is controllable by cations. However, a second population immediately self-assembles upon purification through a non-regulatable pathway, rendering larger nanoparticles with specific biological properties. The structural analyses of both model proteins and nanoparticles revealed important conformational variability in the building blocks. This fact renders different structural and functional categories of the final soft materials resulting from the participation of energetically unstable intermediates in the oligomerization process. These data illustrate the complexity of the His-mediated protein assembling in recombinant proteins but they also offer clues for a better design and refinement of protein-based nanomedicines, which, resulting from biological fabrication, show an architectonic flexibility unusual among biomaterials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery

  • Serna, Naroa|||0000-0001-5682-8198
  • Pallarès, Victor|||0000-0002-9851-0345
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Parladé, Eloi|||0000-0001-5750-550X
  • Rueda, Ariana|||0000-0001-7588-9279
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Sierra, Jorge|||0000-0002-7966-0356
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
Self-assembling non-immunoglobulin scaffold proteins are a promising class of nanoscale carriers for drug delivery and interesting alternatives to antibody-based carriers that are not sufficiently efficient in systemic administration. To exploit their potentialities in clinics, protein scaffolds need to be further tailored to confer appropriate targeting and to overcome their potential immunogenicity, short half-life in plasma and proteolytic degradation. We have here engineered three human scaffold proteins as drug carrier nanoparticles to target the cytokine receptor CXCR4, a tumoral cell surface marker of high clinical relevance. The capability of these scaffolds for the selective delivery of Monomethyl auristatin E has been comparatively evaluated in a disseminated mouse model of human, CXCR4+ acute myeloid leukemia. Monomethyl auristatin E is an ultra-potent anti-mitotic drug used against a range of hematological neoplasias, which because of its high toxicity is not currently administered as a free drug but as payload in antibody-drug conjugates. The protein nanoconjugates generated here offer a collective strength of simple manufacturing process, high proteolytic and structural stability and multivalent ligand receptor interactions that result in a highly efficient and selective delivery of the payload drug and in a potent anticancer effect. The approach shown here stresses this class of human scaffold proteins as promising alternatives to antibodies for targeted drug delivery in the rapidly evolving drug development landscape.
Dipòsit Digital de Documents de la UAB
Datos de investigación Set de datos (Dataset)

Raw data to support the manuscript "Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery"

  • Serna, Naroa|||0000-0001-5682-8198
  • Pallarès, Victor|||0000-0002-9851-0345
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Parladé, Eloi|||0000-0001-5750-550X
  • Rueda, Ariana|||0000-0001-7588-9279
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Sierra, Jorge|||0000-0002-7966-0356
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
Raw data of a set of experiments aimed to explore the suitability of different human proteins as scaffold for targeted nanocarriers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials

  • Serna, Naroa|||0000-0001-5682-8198
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Núñez, Yáiza|||0000-0001-7268-2125
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Villaverde, Antonio|||0000-0002-2615-4521
The sustained release of small, tumor-targeted cytotoxic drugs is an unmet need in cancer therapies, which usually rely on punctual administration regimens of non-targeted drugs. Here, we have developed a novel concept of protein-drug nanoconjugates, which are packaged as slow-releasing chemically hybrid depots and sustain a prolonged secretion of the therapeutic agent. For this, we covalently attached hydrophobic molecules (including the antitumoral drug Monomethyl Auristatin E) to a protein targeting a tumoral cell surface marker abundant in several human neoplasias, namely the cytokine receptor CXCR4. By this, a controlled aggregation of the complex is achieved, resulting in mechanically stable protein-drug microparticles. These materials, which are mimetics of bacterial inclusion bodies and of mammalian secretory granules, allow the slow leakage of fully functional conjugates at the nanoscale, both in vitro and in vivo. Upon subcutaneous administration in a mouse model of human CXCR4 + lymphoma, the protein-drug depots release nanoconjugates for at least 10 days, which accumulate in the tumor with a potent antitumoral effect. The modification of scaffold cell-targeted proteins by hydrophobic drug conjugation is then shown as a novel transversal platform for the design of slow releasing protein-drug depots, with potential application in a broad spectrum of clinical settings.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma

  • Rioja Blanco, Elisa|||0000-0003-4176-8772
  • Arroyo Solera, Irene|||0000-0003-0425-1483
  • Álamo, Patricia|||0000-0003-0510-5701
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Quer, Miquel|||0000-0003-2563-6729
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ramon|||0000-0003-2661-9525
Therapy resistance, which leads to the development of loco-regional relapses and distant metastases after treatment, constitutes one of the major problems that head and neck squamous cell carcinoma (HNSCC) patients currently face. Thus, novel therapeutic strategies are urgently needed. Targeted drug delivery to the chemokine receptor 4 (CXCR4) represents a promising approach for HNSCC management. In this context, we have developed the self-assembling protein nanotoxins T22-PE24-H6 and T22-DITOX-H6, which incorporate the de-immunized catalytic domain of Pseudomonas aeruginosa (PE24) exotoxin A and the diphtheria exotoxin (DITOX) domain, respectively. Both nanotoxins contain the T22 peptide ligand to specifically target CXCR4-overexpressing HNSCC cells. In this study, we evaluate the potential use of T22-PE24-H6 and T22-DITOX-H6 nanotoxins for the treatment of HNSCC. T22-PE24-H6 and T22-DITOX-H6 CXCR4-dependent cytotoxic effect was evaluated in vitro in two different HNSCC cell lines. Both nanotoxins cell death mechanisms were assessed in HNSCC cell lines by phase-contrast microscopy, AnnexinV/ propidium iodide (PI) staining, lactate dehydrogenase (LDH) release assays, and western blotting. Nanotoxins antitumor effect in vivo was studied in a CXCR4 + HNSCC subcutaneous mouse model. Immunohistochemistry, histopathology, and toxicity analyses were used to evaluate both nanotoxins antitumor effect and possible treatment toxicity. GSMDE and CXCR4 expression in HNSCC patient tumor samples was also assessed by immunohistochemical staining. First, we found that both nanotoxins exhibit a potent CXCR4-dependent cytotoxic effect in vitro. Importantly, nanotoxin treatment triggered caspase-3/Gasdermin E (GSDME)-mediated pyroptosis. The activation of this alternative cell death pathway that differs from traditional apoptosis, becomes a promising strategy to bypass therapy resistance. In addition, T22-PE24-H6 and T22-DITOX-H6 displayed a potent antitumor effect in the absence of systemic toxicity in a CXCR4 + subcutaneous HNSCC mouse model. Lastly, GSDME was found to be overexpressed in tumor tissue from HNSCC patients, highlighting the relevance of this strategy. Altogether, our results show that T22-PE24-H6 and T22-DITOX-H6 represent a promising therapy for HNSCC patients. Remarkably, this is the first study showing that both nanotoxins are capable of activating caspase-3/GSDME-dependent pyroptosis, opening a novel avenue for HNSCC treatment. The online version contains supplementary material available at 10.1186/s13046-022-02267-8.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4 + Diffuse Large B-Cell Lymphoma Cells

  • Falgàs, Aïda|||0000-0002-5040-2265
  • Pallarès, Victor|||0000-0002-9851-0345
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Núñez, Yáiza|||0000-0001-7268-2125
  • Sierra, Jorge|||0000-0002-7966-0356
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ma Antonia|||0000-0002-1438-8515
  • Álamo, Patricia|||0000-0003-0510-5701
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
Around 40-50% of diffuse large-B cell lymphoma (DLBCL) patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many ongoing clinical trials for DLBCL patients involve microtubule targeting agents (MTAs), however, their anticancer activity is limited by severe side effects. Therefore, we chose to improve the therapeutic window of the MTA monomethyl auristatin E developing a nanoconjugate, T22-AUR, that selectively targets the CXCR4 receptor, which is overexpressed in many DLBCL cells (CXCR4 +) and associated with poor prognosis. The T22-AUR specificity towards CXCR4 receptor was performed by flow cytometry in different DLBCL cell lines and running biodistribution assays in a subcutaneous mouse model bearing CXCR4 + DLBCL cells. Moreover, we determined T22-AUR cytotoxicity using cell viability assays, cell cycle analysis, DAPI staining and immunohistochemistry. Finally, the T22-AUR antineoplastic effect was evaluated in vivo in an extranodal CXCR4 + DLBCL mouse model whereas the toxicity analysis was assessed by histopathology in non-infiltrated mouse organs and by in vitro cytotoxic assays in human PBMCs. We demonstrate that the T22-AUR nanoconjugate displays CXCR4-dependent targeting and internalization in CXCR4 + DLBCL cells in vitro as well as in a subcutaneous DLBCL mouse model. Moreover, it shows high cytotoxic effect in CXCR4 + DLBCL cells, including induction of G2/M mitotic arrest, DNA damage, mitotic catastrophe and apoptosis. Furthermore, the nanoconjugate shows a potent reduction in lymphoma mouse dissemination without histopathological alterations in non-DLBCL infiltrated organs. Importantly, T22-AUR also exhibits lack of toxicity in human PBMCs. T22-AUR exerts in vitro and in vivo anticancer effect on CXCR4 + DLBCL cells without off-target toxicity. Thus, T22-AUR promises to become an effective therapy for CXCR4 + DLBCL patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Antibacterial activity of T22, a specific peptidic ligand of the tumoral marker CXCR4

  • Serna, Naroa|||0000-0001-5682-8198
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Conchillo-Solé, Oscar|||0000-0003-4266-246X
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Mangues, Ramon|||0000-0003-2661-9525
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Daura i Ribera, Xavier|||0000-0001-9235-6730
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
CXCR4 is a cytokine receptor used by HIV during cell attachment and infection. Overexpressed in the cancer stem cells of more than 20 human neoplasias, CXCR4 is a convenient antitumoral drug target. T22 is a polyphemusin-derived peptide and an effective CXCR4 ligand. Its highly selective CXCR4 binding can be exploited as an agent for the cell-targeted delivery and internalization of associated antitumor drugs. Sharing chemical and structural traits with antimicrobial peptides (AMPs), the capability of T22 as an antibacterial agent remains unexplored. Here, we have detected T22-associated antimicrobial activity and biofilm formation inhibition over Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa, in a spectrum broader than the reference AMP GWH1. In contrast to GWH1, T22 shows neither cytotoxicity over mammalian cells nor hemolytic activity and is active when displayed on protein-only nanoparticles through genetic fusion. Under the pushing need for novel antimicrobial agents, the discovery of T22 as an AMP is particularly appealing, not only as its mere addition to the expanding catalogue of antibacterial drugs. The recognized clinical uses of T22 might allow its combined and multivalent application in complex clinical conditions, such as colorectal cancer, that might benefit from the synchronous destruction of cancer stem cells and local bacterial biofilms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Poly-Histidine Tag H6 Mediates Structural and Functional Properties of Disintegrating, Protein-Releasing Inclusion Bodies

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Serna, Naroa|||0000-0001-5682-8198
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Nolan, Verónica
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
The coordination between histidine-rich peptides and divalent cations supports the formation of nano- and micro-scale protein biomaterials, including toxic and non-toxic functional amyloids, which can be adapted as drug delivery systems. Among them, inclusion bodies (IBs) formed in recombinant bacteria have shown promise as protein depots for time-sustained protein release. We have demonstrated here that the hexahistidine (H6) tag, fused to recombinant proteins, impacts both on the formation of bacterial IBs and on the conformation of the IB-forming protein, which shows a higher content of cross-beta intermolecular interactions in H6-tagged versions. Additionally, the addition of EDTA during the spontaneous disintegration of isolated IBs largely affects the protein leakage rate, again protein release being stimulated in His-tagged materials. This event depends on the number of His residues but irrespective of the location of the tag in the protein, as it occurs in either C-tagged or N-tagged proteins. The architectonic role of H6 in the formation of bacterial IBs, probably through coordination with divalent cations, offers an easy approach to manipulate protein leakage and to tailor the applicability of this material as a secretory amyloidal depot in different biomedical interfaces. In addition, the findings also offer a model to finely investigate, in a simple set-up, the mechanics of protein release from functional secretory amyloids.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model

  • Rioja Blanco, Elisa|||0000-0003-4176-8772
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Arroyo Solera, Irene|||0000-0003-0425-1483
  • Álamo, Patricia|||0000-0003-0510-5701
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Quer, Miquel|||0000-0003-2563-6729
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • León i Vintró, Xavier|||0000-0001-6286-630X
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ramon|||0000-0003-2661-9525
Loco-regional recurrences and metastasis represent the leading causes of death in head and neck squamous cell carcinoma (HNSCC) patients, highlighting the need for novel therapies. Chemokine receptor 4 (CXCR4) has been related to loco-regional and distant recurrence and worse patient prognosis. In this regard, we developed a novel protein nanoparticle, T22-DITOX-H6, aiming to selectively deliver the diphtheria toxin cytotoxic domain to CXCR4+ HNSCC cells. The antimetastatic effect of T22-DITOX-H6 was evaluated in vivo in an orthotopic mouse model. IVIS imaging system was utilized to assess the metastatic dissemination in the mouse model. Immunohistochemistry and histopathological analyses were used to study the CXCR4 expression in the cancer cells, to evaluate the effect of the nanotoxin treatment, and its potential off-target toxicity. In this study, we report that CXCR4+ cancer cells were present in the invasive tumor front in an orthotopic mouse model. Upon repeated T22-DITOX-H6 administration, the number of CXCR4+ cancer cells was significantly reduced. Similarly, nanotoxin treatment effectively blocked regional and distant metastatic dissemination in the absence of systemic toxicity in the metastatic HNSCC mouse model. The repeated administration of T22-DITOX-H6 clearly abrogates tumor invasiveness and metastatic dissemination without inducing any off-target toxicity. Thus, T22-DITOX-H6 holds great promise for the treatment of CXCR4+ HNSCC patients presenting worse prognosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Ion-dependent slow protein release from in vivo disintegrating micro-granules

  • Álamo, Patricia|||0000-0003-0510-5701
  • Parladé, Eloi|||0000-0001-5750-550X
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
Through the controlled addition of divalent cations, polyhistidine-tagged proteins can be clustered in form of chemically pure and mechanically stable micron-scale particles. Under physiological conditions, these materials act as self-disintegrating protein depots for the progressive release of the forming polypeptide, with potential applications in protein drug delivery, diagnosis, or theragnosis. Here we have explored the in vivo disintegration pattern of a set of such depots, upon subcutaneous administration in mice. These microparticles were fabricated with cationic forms of either Zn, Ca, Mg, or Mn, which abound in the mammalian body. By using a CXCR4-targeted fluorescent protein as a reporter building block we categorized those cations regarding their ability to persist in the administration site and to sustain a slow release of functional protein. Ca and specially Zn have been observed as particularly good promoters of time-prolonged protein leakage. The released polypeptides result is available for selective molecular interactions, such as specific fluorescent labeling of tumor tissues, in which the protein reaches nearly steady levels.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4 + head and neck squamous cell carcinoma tumors

  • Rioja Blanco, Elisa|||0000-0003-4176-8772
  • Arroyo Solera, Irene|||0000-0003-0425-1483
  • Álamo, Patricia|||0000-0003-0510-5701
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Quer, Miquel|||0000-0003-2563-6729
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • León i Vintró, Xavier|||0000-0001-6286-630X
Loco-regional recurrences and distant metastases represent the main cause of head and neck squamous cell carcinoma (HNSCC) mortality. The overexpression of chemokine receptor 4 (CXCR4) in HNSCC primary tumors associates with higher risk of developing loco-regional recurrences and distant metastases, thus making CXCR4 an ideal entry pathway for targeted drug delivery. In this context, our group has generated the self-assembling protein nanocarrier T22-GFP-H6, displaying multiple T22 peptidic ligands that specifically target CXCR4. This study aimed to validate T22-GFP-H6 as a suitable nanocarrier to selectively deliver cytotoxic agents to CXCR4 + tumors in a HNSCC model. Here we demonstrate that T22-GFP-H6 selectively internalizes in CXCR4 + HNSCC cells, achieving a high accumulation in CXCR4 + tumors in vivo, while showing negligible nanocarrier distribution in non-tumor bearing organs. Moreover, this T22-empowered nanocarrier can incorporate bacterial toxin domains to generate therapeutic nanotoxins that induce cell death in CXCR4-overexpressing tumors in the absence of histological alterations in normal organs. Altogether, these results show the potential use of this T22-empowered nanocarrier platform to incorporate polypeptidic domains of choice to selectively eliminate CXCR4 + cells in HNSCC. Remarkably, to our knowledge, this is the first study testing targeted protein-only nanoparticles in this cancer type, which may represent a novel treatment approach for HNSCC patients. The self-assembling protein nanocarrier T22-GFP-H6, that specifically targets CXCR4, was designed to selectively deliver cytotoxic agents to CXCR4 + tumors in a head and neck squamous cell carcinoma model.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model

  • Pallarès, Victor|||0000-0002-9851-0345
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Aviñó, Ana|||0000-0003-3047-738X
  • Núñez, Yáiza|||0000-0001-7268-2125
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Serna, Naroa|||0000-0001-5682-8198
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Álamo, Patricia|||0000-0003-0510-5701
  • Sierra, Jorge|||0000-0002-7966-0356
  • Cedó, Lídia|||0000-0003-4354-3411
  • Eritja, Ramon|||0000-0001-5383-9334
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
Current therapy in acute myeloid leukemia (AML) is based on chemotherapeutic drugs administered at high doses, lacking targeting selectivity and displaying poor therapeutic index because of severe adverse effects. Here, we develop a novel nanoconjugate that combines a self-assembled, multivalent protein nanoparticle, targeting the CXCR4 receptor, with an Oligo-Ara-C prodrug, a pentameric form of Ara-C, to highly increase the delivered payload to target cells. This 13.4 nm T22-GFP-H6-Ara-C nanoconjugate selectively eliminates CXCR4 AML cells, which are protected by its anchoring to the bone marrow (BM) niche, being involved in AML progression and chemotherapy resistance. This nanoconjugate shows CXCR4-dependent internalization and antineoplastic activity in CXCR4 AML cells in vitro. Moreover, repeated T22-GFP-H6-Ara-C administration selectively eliminates CXCR4 leukemic cells in BM, spleen and liver. The leukemic dissemination blockage induced by T22-GFP-H6-Ara-C is significantly more potent than buffer or Oligo-Ara-C-treated mice, showing no associated on-target or off-target toxicity and, therefore, reaching a highly therapeutic window. In conclusion, T22-GFP-H6-Ara-C exploits its 11 ligands-multivalency to enhance target selectivity, while the Oligo-Ara-C prodrug multimeric form increases 5-fold its payload. This feature combination offers an alternative nanomedicine with higher activity and greater tolerability than current intensive or non-intensive chemotherapy for AML patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

In vitro fabrication of microscale secretory granules

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Parladé, Eloi|||0000-0001-5750-550X
  • Álamo, Patricia|||0000-0003-0510-5701
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
Advanced medical treatments involving drug delivery require fully biocompatible materials with the ability to release functional drugs in a time-prolonged way. Ideally, the delivered molecules should be self-contained as chemically homogenous entities to prevent the use of potentially toxic scaffolds or hold matrices. In nature, peptidic hormones are self-stored in protein-only secretory granules formed by the reversible coordination of Zn and histidine residues. Inspired by this concept, an in vitro transversal procedure is developed, analyzed, and comparatively applied for the fabrication of protein-only secretory granules at the microscale. These materials can be produced from any polyhistidine-tagged protein using physiological concentrations of Zn as a potent and versatile glue-like agent. The screening of granules formed by 12 engineered and nonengineered proteins at different Zn concentrations revealed optimal fabrication conditions and the consequent release profiles. Moreover, the functional and structural properties of the delivered protein are fully validated using a drug-targeting protein platform in a mouse model of human colorectal cancer. In summary, short histidine tags allow the packaging of structurally and functionally dissimilar polypeptides, which supports the proposed fabrication method as a powerful protocol extensible to diverse clinical scenarios in which slow protein drug delivery is required.
Dipòsit Digital de Documents de la UAB
Datos de investigación Set de datos (Dataset)

Raw data from a MS with the tentative title, Cell penetration of receptor-targeted protein-only nanoparticles assisted by the translocation domain of the diphtheria toxin

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Parladé, Eloi|||0000-0001-5750-550X
  • Serna, Naroa|||0000-0001-5682-8198
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
Raw data of a set of experiments aimed to explore the properties of the diftheria toxin translocation domain placed in receptor-targeted self-assembling nanoparticles based on recombinant proteins.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Protein scaffolds in human clinics

  • Cano-Garrido, Olivia|||0000-0002-5504-2131
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Parladé, Eloi|||0000-0001-5750-550X
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Serna, Naroa|||0000-0001-5682-8198
Fundamental clinical areas such as drug delivery and regenerative medicine require biocompatible materials as mechanically stable scaffolds or as nanoscale drug carriers. Among the wide set of emerging biomaterials, polypeptides offer enticing properties over alternative polymers, including full biocompatibility, biodegradability, precise interactivity, structural stability and conformational and functional versatility, all of them tunable by conventional protein engineering. However, proteins from non-human sources elicit immunotoxicities that might bottleneck further development and narrow their clinical applicability. In this context, selecting human proteins or developing humanized protein versions as building blocks is a strict demand to design non-immunogenic protein materials. We review here the expanding catalogue of human or humanized proteins tailored to execute different levels of scaffolding functions and how they can be engineered as self-assembling materials in form of oligomers, polymers or complex networks. In particular, we emphasize those that are under clinical development, revising their fields of applicability and how they have been adapted to offer, apart from mere mechanical support, highly refined functions and precise molecular interactions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Diphtheria Toxin Translocation Domain Impairs Receptor Selectivity in Cancer Cell-Targeted Protein Nanoparticles

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Parladé, Eloi|||0000-0001-5750-550X
  • Serna, Naroa|||0000-0001-5682-8198
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
Protein-based materials intended as nanostructured drugs or drug carriers are progressively gaining interest in nanomedicine, since their structure, assembly and cellular interactivity can be tailored by recruiting functional domains. The main bottleneck in the development of deliverable protein materials is the lysosomal degradation that follows endosome maturation. This is especially disappointing in the case of receptor-targeted protein constructs, which, while being highly promising and in demand in precision medicines, enter cells via endosomal/lysosomal routes. In the search for suitable protein agents that might promote endosome escape, we have explored the translocation domain (TD) of the diphtheria toxin as a functional domain in CXCR4-targeted oligomeric nanoparticles designed for cancer therapies. The pharmacological interest of such protein materials could be largely enhanced by improving their proteolytic stability. The incorporation of TD into the building blocks enhances the amount of the material detected inside of exposed CXCR4 cells up to around 25-fold, in absence of cytotoxicity. This rise cannot be accounted for by endosomal escape, since the lysosomal degradation of the new construct decreases only moderately. On the other hand, a significant loss in the specificity of the CXCR4-dependent cellular penetration indicates the unexpected role of the toxin segment as a cell-penetrating peptide in a dose-dependent and receptor-independent fashion. These data reveal that the diphtheria toxin TD displayed on receptor-targeted oligomeric nanoparticles partially abolishes the exquisite receptor specificity of the parental material and it induces nonspecific internalization in mammalian cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Recombinant vaccines in 2022, a perspective from the cell factory

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Parladé, Eloi|||0000-0001-5750-550X
  • Vázquez, Esther|||0000-0003-1052-0424
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
The last big outbreaks of Ebola fever in Africa, the thousands of avian influenza outbreaks across Europe, Asia, North America and Africa, the emergence of monkeypox virus in Europe and specially the COVID-19 pandemics have globally stressed the need for efficient, cost-effective vaccines against infectious diseases. Ideally, they should be based on transversal technologies of wide applicability. In this context, and pushed by the above-mentioned epidemiological needs, new and highly sophisticated DNA-or RNA-based vaccination strategies have been recently developed and applied at large-scale. Being very promising and effective, they still need to be assessed regarding the level of conferred long-term protection. Despite these fast-developing approaches, subunit vaccines, based on recombinant proteins obtained by conventional genetic engineering, still show a wide spectrum of interesting potentialities and an important margin for further development. In the 80's, the first vaccination attempts with recombinant vaccines consisted in single structural proteins from viral pathogens, administered as soluble plain versions. In contrast, more complex formulations of recombinant antigens with particular geometries are progressively generated and explored in an attempt to mimic the multifaceted set of stimuli offered to the immune system by replicating pathogens. The diversity of recombinant antimicrobial vaccines and vaccine prototypes is revised here considering the cell factory types, through relevant examples of prototypes under development as well as already approved products.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases

  • Sala, Rita
  • Rioja Blanco, Elisa|||0000-0003-4176-8772
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Álamo, Patricia|||0000-0003-0510-5701
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • López Pousa, Antonio|||0000-0003-1066-3951
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
Colorectal cancer (CRC) remains the third cause of cancer-related mortality in Western countries, metastases are the main cause of death. CRC treatment remains limited by systemic toxicity and chemotherapy resistance. Therefore, nanoparticle-mediated delivery of cytotoxic agents selectively to cancer cells represents an efficient strategy to increase the therapeutic index and overcome drug resistance. We have developed the T22-PE24-H6 therapeutic protein-only nanoparticle that incorporates the exotoxin A from Pseudomonas aeruginosa to selectively target CRC cells because of its multivalent ligand display that triggers a high selectivity interaction with the CXCR4 receptor overexpressed on the surface of CRC stem cells. We here observed a CXCR4-dependent cytotoxic effect for T22-PE24-H6, which was not mediated by apoptosis, but instead capable of inducing a time-dependent and sequential activation of pyroptotic markers in CRC cells in vitro. Next, we demonstrated that repeated doses of T22-PE24-H6 inhibit tumor growth in a subcutaneous CXCR4 CRC model, also through pyroptotic activation. Most importantly, this nanoparticle also blocked the development of lymphatic and hematogenous metastases, in a highly aggressive CXCR4 SW1417 orthotopic CRC model, in the absence of systemic toxicity. This targeted drug delivery approach supports for the first time the clinical relevance of inducing GSDMD-dependent pyroptosis, a cell death mechanism alternative to apoptosis, in CRC models, leading to the selective elimination of CXCR4 cancer stem cells, which are associated with resistance, metastases and anti-apoptotic upregulation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4+ lymphoma cells without toxicity in immunocompromised and immunocompetent mice

  • Falgàs, Aïda|||0000-0002-5040-2265
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Núñez, Yáiza|||0000-0001-7268-2125
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Aragó, Marc|||0000-0002-9645-0131
  • Álamo, Patricia|||0000-0003-0510-5701
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Sierra, Jorge|||0000-0002-7966-0356
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
High rates of relapsed and refractory diffuse large B-cell lymphoma (DLBCL) patients and life-threatening side effects associated with immunochemotherapy make an urgent need to develop new therapies for DLBCL patients. Immunotoxins seem very potent anticancer therapies but their use is limited because of their high toxicity. Accordingly, the self-assembling polypeptidic nanoparticle, T22-DITOX-H6, incorporating the diphtheria toxin and targeted to CXCR4 receptor, which is overexpressed in DLBCL cells, could offer a new strategy to selectively eliminate CXCR4 DLBCL cells without adverse effects. In these terms, our work demonstrated that T22-DITOX-H6 showed high specific cytotoxicity towards CXCR4 DLBCL cells at the low nanomolar range, which was dependent on caspase-3 cleavage, PARP activation and an increase of cells in early/late apoptosis. Repeated nanoparticle administration induced antineoplastic effect, in vivo and ex vivo, in a disseminated immunocompromised mouse model generated by intravenous injection of human luminescent CXCR4 DLBCL cells. Moreover, T22-DITOX-H6 inhibited tumor growth in a subcutaneous immunocompetent mouse model bearing mouse CXCR4 lymphoma cells in the absence of alterations in the hemogram, liver or kidney injury markers or on-target or off-target organ histology. Thus, T22-DITOX-H6 demonstrates a selective cytotoxicity towards CXCR4 DLBCL cells without the induction of toxicity in non-lymphoma infiltrated organs nor hematologic toxicity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Potent Anticancer Activity of CXCR4-Targeted Nanostructured Toxins in Aggressive Endometrial Cancer Models

  • Medina-Gutiérrez, Esperanza
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Álamo, Patricia|||0000-0003-0510-5701
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ramon|||0000-0003-2661-9525
Patients with advanced endometrial cancer (EC) show poor outcomes. Thus, the development of new therapeutic approaches to prevent metastasis development in high-risk patients is an unmet need. CXCR4 is overexpressed in EC tumor tissue, epitomizing an unexploited therapeutic target for this malignancy. The in vitro antitumor activity of two CXCR4-targeted nanoparticles, including either the C. diphtheriae (T22-DITOX-H6) or P. aeruginosa (T22-PE24-H6) toxin, was evaluated using viability assays. Apoptotic activation was assessed by DAPI and caspase-3 and PARP cleavage in cell blocks. Both nanotoxins were repeatedly administrated to a subcutaneous EC mouse model, whereas T22-DITOX-H6 was also used in a highly metastatic EC orthotopic model. Tumor burden was assessed through bioluminescence, while metastatic foci and toxicity were studied using histological or immunohistochemical analysis. We found that both nanotoxins exerted a potent antitumor effect both in vitro and in vivo via apoptosis and extended the survival of nanotoxin-treated mice without inducing any off-target toxicity. Repeated T22-DITOX-H6 administration in the metastatic model induced a dramatic reduction in tumor burden while significantly blocking peritoneal, lung and liver metastasis without systemic toxicity. Both nanotoxins, but especially T22-DITOX-H6, represent a promising therapeutic alternative for EC patients that have a dismal prognosis and lack effective therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Recombinant Proteins for Assembling as Nano- and Micro-Scale Materials for Drug Delivery, A Host Comparative Overview

  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Márquez-Martínez, Merce|||0000-0003-2157-5850
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Ferreira, Luis|||0000-0002-4883-1693
  • Vázquez, Esther|||0000-0003-1052-0424
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Parladé, Eloi|||0000-0001-5750-550X
By following simple protein engineering steps, recombinant proteins with promising applications in the field of drug delivery can be assembled in the form of functional materials of increasing complexity, either as nanoparticles or nanoparticle-leaking secretory microparticles. Among the suitable strategies for protein assembly, the use of histidine-rich tags in combination with coordinating divalent cations allows the construction of both categories of material out of pure polypeptide samples. Such molecular crosslinking results in chemically homogeneous protein particles with a defined composition, a fact that offers soft regulatory routes towards clinical applications for nanostructured protein-only drugs or for protein-based drug vehicles. Successes in the fabrication and final performance of these materials are expected, irrespective of the protein source. However, this fact has not yet been fully explored and confirmed. By taking the antigenic RBD domain of the SARS-CoV-2 spike glycoprotein as a model building block, we investigated the production of nanoparticles and secretory microparticles out of the versions of recombinant RBD produced by bacteria (Escherichia coli), insect cells (Sf9), and two different mammalian cell lines (namely HEK 293F and Expi293F). Although both functional nanoparticles and secretory microparticles were effectively generated in all cases, the technological and biological idiosyncrasy of each type of cell factory impacted the biophysical properties of the products. Therefore, the selection of a protein biofabrication platform is not irrelevant but instead is a significant factor in the upstream pipeline of protein assembly into supramolecular, complex, and functional materials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lymphocyte infiltration and antitumoral effect promoted by cytotoxic inflammatory proteins formulated as self-assembling, protein-only nanoparticles

  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Serna, Naroa|||0000-0001-5682-8198
  • Imedio, Laura
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
Two human proteins involved in the inflammatory cell death, namely Gasdermin D (GSDMD) and the Mixed Lineage Kinase Domain-Like (MLKL) protein have been engineered to accommodate an efficient ligand of the tumoral cell marker CXCR4, and a set of additional peptide agents that allow their spontaneous self-assembling. Upon production in bacterial cells and further purification, both proteins organized as stable nanoparticles of 46 and 54 nm respectively, that show, in this form, a moderate but dose-dependent cytotoxicity in cell culture. In vivo, and when administered in mouse models of colorectal cancer through repeated doses, the nanoscale forms of tumor-targeted GSDMD and, at a lesser extent, of MLKL promoted CD8+ and CD20+ lymphocyte infiltration in the tumor and an important reduction of tumor size, in absence of systemic toxicity. The potential of these novel pharmacological agents as anticancer drugs is discussed in the context of synergistic approaches to more effective cancer treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo

  • Núñez, Yáiza|||0000-0001-7268-2125
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Serna, Naroa|||0000-0001-5682-8198
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Garrido Diaz, Ana|||0000-0002-5297-8946
  • Sierra, Jorge|||0000-0002-7966-0356
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
Despite advances in the development of targeted therapies for acute myeloid leukemia (AML), most patients relapse. For that reason, it is still necessary to develop novel therapies that improve treatment effectiveness and overcome drug resistance. We developed T22-PE24-H6, a protein nanoparticle that contains the exotoxin A from the bacterium Pseudomonas aeruginosa and is able to specifically deliver this cytotoxic domain to CXCR4 + leukemic cells. Next, we evaluated the selective delivery and antitumor activity of T22-PE24-H6 in CXCR4 + AML cell lines and BM samples from AML patients. Moreover, we assessed the in vivo antitumor effect of this nanotoxin in a disseminated mouse model generated from CXCR4 + AML cells. T22-PE24-H6 showed a potent, CXCR4-dependent antineoplastic effect in vitro in the MONO-MAC-6 AML cell line. In addition, mice treated with nanotoxins in daily doses reduced the dissemination of CXCR4 + AML cells compared to buffer-treated mice, as shown by the significant decrease in BLI signaling. Furthermore, we did not observe any sign of toxicity or changes in mouse body weight, biochemical parameters, or histopathology in normal tissues. Finally, T22-PE24-H6 exhibited a significant inhibition of cell viability in CXCR4 high AML patient samples but showed no activity in CXCR4 low samples. These data strongly support the use of T22-PE24-H6 therapy to benefit high-CXCR4-expressing AML patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Probing the Biosafety of Implantable Artificial Secretory Granules for the Sustained Release of Bioactive Proteins

  • Álamo, Patricia|||0000-0003-0510-5701
  • Parladé, Eloi|||0000-0001-5750-550X
  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Ferreira, Luís C.S.
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Among bio-inspired protein materials, secretory protein microparticles are of clinical interest as self-contained, slow protein delivery platforms that mimic secretory granules of the human endocrine system, in which the protein is both the drug and the scaffold. Upon subcutaneous injection, their progressive disintegration results in the sustained release of the building block polypeptides, which reach the bloodstream for systemic distribution and subsequent biological effects. Such entities are easily fabricated in vitro by Zn-assisted cross-molecular coordination of histidine residues. Using cationic Zn for the assembly of selected pure protein species and in the absence of any heterologous holding material, these granules are expected to be nontoxic and therefore adequate for different clinical uses. However, such presumed biosafety has not been so far confirmed and the potential protein dosage threshold not probed yet. By selecting the receptor binding domain (RBD) from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein as a model protein and using a mouse lab model, we have explored the toxicity of RBD-made secretory granules at increasing doses up to ∼100 mg/kg of animal weight. By monitoring body weight and biochemical blood markers and through the histological scrutiny of main tissues and organs, we have not observed systemic toxicity. Otherwise, the bioavailability of the material was demonstrated by the induction of specific antibody responses. The presented data confirm the intrinsic biosafety of artificial secretory granules made by recombinant proteins and prompt their further clinical development as self-contained and dynamic protein reservoirs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

High-precision targeting and destruction of cancer-associated PDGFR-β+ stromal fibroblasts through self-assembling, protein-only nanoparticles

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Serna, Naroa|||0000-0001-5682-8198
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Sánchez Chardi, Alejandro|||0000-0002-8789-1883
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Vázquez, Esther|||0000-0003-1052-0424
  • Mangues, Ramon|||0000-0003-2661-9525
The need for more effective and precision medicines for cancer has pushed the exploration of new materials appropriate for drug delivery and imaging, and alternative receptors for targeting. Among the most promising strategies, finding suitable cell surface receptors and targeting agents for cancer-associated platelet derived growth factor receptor β (PDGFR-β)+ stromal fibroblasts is highly appealing. As a neglected target, this cell type mechanically and biologically supports the growth, progression, and infiltration of solid tumors in non-small cell lung, breast, pancreatic, and colorectal cancers. We have developed a family of PDGFR-β-targeted nanoparticles based on biofabricated, self-assembling proteins, upon hierarchical and iterative selective processes starting from four initial candidates. The modular protein PDGFD-GFP-H6 is well produced in recombinant bacteria, resulting in structurally robust oligomeric particles that selectively penetrates into PDGFR-β+ stromal fibroblasts in a dose-dependent manner, by means of the PDGFR-β ligand PDGFD. Upon in vivo administration, these GFP-carrying protein nanoparticles precisely accumulate in tumor tissues and enlighten them for IVIS observation. When GFP is replaced by a microbial toxin, selective tumor tissue destruction is observed associated with a significant reduction in tumor volume growth. The presented data validate the PDGFR-β/PDGFD pair as a promising toolbox for targeted drug delivery in the tumor microenvironment and oligomeric protein nanoparticles as a powerful instrument to mediate highly selective biosafe targeting in cancer through non-cancer cells. Statement of significance: We have developed a transversal platform for nanoparticle-based drug delivery into cancer-associated fibroblasts. This is based on the engineered modular protein PDGFD-GFP-H6 that spontaneously self-assemble and selectively penetrates into PDGFR-β+ stromal fibroblasts in a dose-dependent manner, by means of the PDGFR-β ligand PDGFD. In vivo, these protein nanoparticles accumulate in tumor and when incorporating a microbial toxin, they destroy tumor tissues with a significant reduction in tumor volume, in absence of side toxicities. The data presented here validate the PDGFR-β/PDGFD pair as a fully versatile toolbox for targeted drug delivery in the tumor microenvironment intended as a synergistic treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Protein features instruct the secretion dynamics from metal-supported synthetic amyloids

  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Hexahistidine-tagged proteins can be clustered by divalent cations into self-containing, dynamic protein depots at the microscale, which under physiological conditions leak functional protein. While such protein granules show promise in clinics as time-sustained drug delivery systems, little is known about how the nature of their components, that is, the protein and the particular cation used as cross-linker, impact on the disintegration of the material and on its secretory performance. By using four model proteins and four different cation formulations to control aggregation, we have here determined a moderate influence of the used cation and a potent impact of some protein properties on the release kinetics and on the final fraction of releasable protein. In particular, the electrostatic charge at the amino terminus and the instability and hydropathicity indexes determine the disintegration profile of the depot. These data offer clues for the fabrication of efficient and fully exploitable secretory granulesthat being biocompatible and chemically homogenous allow their tailored use as drug delivery platforms in biological systems.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enhanced recombinant protein capture, purity and yield from crude bacterial cell extracts by N-Lauroylsarcosine-assisted affinity chromatography

  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
Background: Recombinant proteins cover a wide range of biomedical, biotechnological, and industrial needs. Although there are diverse available protocols for their purification from cell extracts or from culture media, many proteins of interest such as those containing cationic domains are difficult to purify, a fact that results in low yields of the final functional product. Unfortunately, this issue prevents the further development and industrial or clinical application of these otherwise interesting products. Results: Aiming at improving the purification of such difficult proteins, a novel procedure has been developed based on supplementing crude cell extracts with non-denaturing concentrations of the anionic detergent N-Lauroylsarcosine. The incorporation of this simple step in the downstream pipeline results in a substantial improvement of the protein capture by affinity chromatography, an increase of protein purity and an enhancement of the overall process yield, being the detergent not detectable in the final product. Conclusion: By taking this approach, which represents a smart repurposing of N-Lauroylsarcosine applied to protein downstream, the biological activity of the protein is not affected. Being technologically simple, the N-Lauroylsarcosine-assisted protein purification might represent a critical improvement in recombinant protein production with wide applicability, thus smothering the incorporation of promising proteins into the protein market.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Endosomal escape for cell-targeted proteins. Going out after going in

  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Parladé, Eloi|||0000-0001-5750-550X
  • Serna, Naroa|||0000-0001-5682-8198
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Protein-based nanocarriers are versatile and biocompatible drug delivery systems. They are of particular interest in nanomedicine as they can recruit multiple functions in a single modular polypeptide. Many cell-targeting peptides or protein domains can promote cell uptake when included in these nanoparticles through receptor-mediated endocytosis. In that way, targeting drugs to specific cell receptors allows a selective intracellular delivery process, avoiding potential side effects of the payload. However, once internalized, the endo-lysosomal route taken by the engulfed material usually results in full degradation, preventing their adequate subcellular localization, bioavailability and subsequent therapeutic effect. Thus, entrapment into endo-lysosomes is a main bottleneck in the efficacy of protein-drug nanomedicines. Promoting endosomal escape and preventing lysosomal degradation would make this therapeutic approach clinically plausible. In this review, we discuss the mechanisms intended to evade lysosomal degradation of proteins, with the most relevant examples and associated strategies, and the methods available to measure that effect. In addition, based on the increasing catalogue of peptide domains tailored to face this challenge as components of protein nanocarriers, we emphasize how their particular mechanisms of action can potentially alter the functionality of accompanying protein materials, especially in terms of targeting and specificity in the delivery process.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Biofabrication of Self-Assembling Covalent Protein Nanoparticles through Histidine-Templated Cysteine Coupling

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Rueda, Ariana|||0000-0001-7588-9279
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Sánchez-Alba, Lucía|||0000-0001-7353-1097
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Atienza-Garriga, Jan|||0000-0001-5537-3566
  • Parladé, Eloi|||0000-0001-5750-550X
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Serna, Naroa|||0000-0001-5682-8198
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
Nanoscale protein materials show increasing applications in biotechnology and biomedicine, addressing catalysis, drug delivery, or tissue engineering. Although protein oligomerization is reachable through several engineering approaches, including the use of divalent cations for histidine-rich stretches, the effectiveness of cation-His binding is influenced by protein conformation, media composition, and chelating agents. Thus, looking for powerful, green, cross-linker-free, and transversal oligomerization platforms, we have built a histidine-templated cysteine-coupling concept. On this basis, we have engineered a Cys-containing, H6-derived His-Cys hybrid tag that enables the spontaneous and efficient self-assembling of tagged proteins into monodisperse nanoparticles through a highly ordered covalent binding process. Although the generated nanostructures are supported by disulfide bridge formation and exclusively reversed by reducing agents but not by chelating agents, the presence of cysteine residues does not disrupt the metal-binding abilities of histidine residues within the tag. This fact allows one to combine the one-step IMAC-based protein purification and, also, the Zn2+-induced formation of higher-order microparticulate materials as nanoparticle-releasing protein-only depots. The dual mode of cross-molecular interactivity shown by the hybrid tag and the structural robustness and stability of the resulting nanoparticles offer wide applicability of the green biofabrication concept proposed here for the further development of clinically usable protein materials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Site-directed cysteine coupling of disulfide-containing non-antibody carrier proteins (THIOCAPs)

  • Rueda, Ariana|||0000-0001-7588-9279
  • Mendoza, Julian Ignacio|||0000-0002-1975-3606
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Parladé, Eloi|||0000-0001-5750-550X
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Paez, David|||0000-0002-5596-6588
  • Aviñó, Ana|||0000-0003-3047-738X
  • Eritja, Ramon|||0000-0001-5383-9334
  • Vázquez, Esther|||0000-0003-1052-0424
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Mangues, Ramon|||0000-0003-2661-9525
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
The development of a new generation of non-antibody protein drug delivery systems requires site-directed conjugation strategies to produce homogeneous, reproducible and scalable nanomedicines. For that, the genetic addition of cysteine residues into solvent-exposed positions allows the thiol-mediated cysteine coupling of therapeutic drugs into protein-based nanocarriers. However, the high reactivity of unpaired cysteine residues usually reduces protein stability, consequently imposing the use of more methodologically demanding purification procedures. This is especially relevant for disulfide-containing nanocarriers, as previously observed in THIOMABs. Moreover, although many protein scaffolds and targeting ligands are also rich in disulfide bridges, the use of these methodologies over emerging non-antibody carrier proteins has been completely neglected. Here, we report the development of a simple and straightforward procedure for a one-step production and site-directed cysteine conjugation of disulfide-containing non-antibody thiolated carrier proteins (THIOCAPs). This method is validated in a fluorescent C-X-C chemokine receptor 4 (CXCR4)-targeted multivalent nano-carrier containing two intramolecular disulfide bridges and one reactive cysteine residue strategically placed into a solvent-exposed position (THIO-T22-GFP-H6) for drug conjugation and in a humanized alternative intended for clinical applications (T22-HSNBT-H6). Thus, we produce very stable, homogeneous and fully functional antitumoral nanoconjugates (THIO-T22-GFP-H6-MMAE and T22-HSNBT-H6-MMAE) that selectively eliminate target cancer cells via CXCR4-receptor. Altogether, the developed methodology appears as a powerful tool for the rational engineering of emerging non-antibody, cell-targeted protein nanocarriers that contain disulfide bridges together with a solvent-exposed reactive cysteine (THIOCAP). This should pave the way for the development of a new generation of stable, homogeneous and efficient nanomedicines.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Efficient Delivery of Antimicrobial Peptides in an Innovative, Slow-Release Pharmacological Formulation

  • Serna, Naroa|||0000-0001-5682-8198
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Aceituno Abarzúa, Patricia|||0000-0002-6015-3274
  • Rojas Peña, Mauricio|||0000-0002-2373-1792
  • Parladé, Eloi|||0000-0001-5750-550X
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Di Somma, Angela|||0000-0003-4916-7875
  • Carratalá, José Vicente|||0000-0001-6950-2939
  • Livieri, Andrea L.
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Villaverde, Antonio|||0000-0002-2615-4521
Both nanostructure and multivalency enhance the biological activities of antimicrobial peptides (AMPs), whose mechanism of action is cooperative. In addition, the efficacy of a particular AMP should benefit from a steady concentration at the local place of action and, therefore, from a slow release after a dynamic repository. In the context of emerging multi-resistant bacterial infections and the urgent need for novel and effective antimicrobial drugs, we tested these concepts through the engineering of four AMPs into supramolecular complexes as pharmacological entities. For that purpose, GWH1, T22, Pt5, and PaD, produced as GFP or human nidogen-based His-tagged fusion proteins, were engineered as self-assembling oligomeric nanoparticles ranging from 10 to 70 nm and further packaged into nanoparticle-leaking submicron granules. Since these materials slowly release functional nanoparticles during their time-sustained unpacking, they are suitable for use as drug depots in vivo. In this context, a particular AMP version (GWH1-NIDO-H6) was selected for in vivo validation in a zebrafish model of a complex bacterial infection. The GWH1-NIDO-H6-secreting protein granules are protective in zebrafish against infection by the multi-resistant bacterium Stenotrophomonas maltophilia, proving the potential of innovative formulations based on nanostructured and slowly released recombinant AMPs in the fight against bacterial infections.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Zinc-Assisted Microscale Granules Made of the SARS-CoV-2 Spike Protein Trigger Neutralizing, Antivirus Antibody Responses

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • Álamo, Patricia|||0000-0003-0510-5701
  • Roher Armentia, Nerea|||0000-0002-6659-4038
  • Chillón Rodríguez, Miguel|||0000-0003-0840-2111
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Márquez, Merce
  • Corchero Nieto, José Luis|||0000-0002-6109-144X
  • Mendoza Moreno, Rosa|||0000-0002-0488-4814
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • Ferrer-Miralles, Neus|||0000-0003-2981-3913
  • Ferreira, Luis|||0000-0002-4883-1693
  • Mangues, Ramon|||0000-0003-2661-9525
  • Vázquez, Esther|||0000-0003-1052-0424
  • Parladé, Eloi|||0000-0001-5750-550X
  • Villaverde, Antonio|||0000-0002-2615-4521
The development of new and more efficient vaccination approaches is a constant need, due to the pressure of historical and emerging infectious diseases and the limited efficacy and universality of the current vaccination technologies. Peptides and recombinant proteins have been explored for decades as subunit vaccines for bacterial and viral infections, presented either as soluble protein species or as virus-like assemblies. Recently, synthetic secretory protein-only microscale granules have been developed as dynamic depots for sustained protein release. They are based on the reversible coordination between ionic Zn and histidine residues, which promotes a fast formation of granular particles in vitro out of soluble protein and a slow release of such building block protein in vivo through the physiological chelation of the metal. Such an endocrine-like platform represents a new drug delivery system fully validated in oncology by which soluble and functional protein drugs are progressively released from the granules and made available for antitumor activities upon subcutaneous administration. By exploring such an approach for immunization here, microparticles made of a recombinant form of the receptor binding domain (RBD) of SARS-CoV-2 were tested as an antigen delivery system for induction of antibody responses against the virus upon administration of the material in the absence of added adjuvants. Also, the comparison between protein materials produced in bacterial, mammalian, or insect cell factories has demonstrated a moderate impact of protein glycosylation on the final immunological performance of the system. Therefore, we propose the consideration of synthetic protein secretory granules as a new sustainable immunization platform based on fully manageable, self-organized, and self-formulated immunogens, aimed at reducing the dosage, costs, and complexity of vaccination regimens.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Nanoparticle-Based Secretory Granules Induce a Specific and Long-Lasting Immune Response through Prolonged Antigen Release

  • Bosch Camós, Laia|||0000-0001-6245-4284
  • Martinez Torro, Carlos|||0000-0002-3529-3355
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Lascorz Lozano, Jara A.|||0000-0002-5823-0728
  • Argilaguet, Jordi|||0000-0001-5924-2774
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Rodriguez, Fernando|||0000-0001-7361-8408
  • Vázquez, Esther|||0000-0003-1052-0424
Developing prolonged antigen delivery systems that mimic long-term exposure to pathogens appears as a promising but still poorly explored approach to reach durable immunities. In this study, we have used a simple technology by which His-tagged proteins can be assembled, assisted by divalent cations, as supramolecular complexes with progressive complexity, namely protein-only nanoparticles and microparticles. Microparticles produced out of nanoparticles are biomimetics of secretory granules from the mammalian hormonal system. Upon subcutaneous administration, they slowly disintegrate, acting as an endocrine-like secretory system and rendering the building block nanoparticles progressively bioavailable. The performance of such materials, previously validated for drug delivery in oncology, has been tested here regarding the potential for time-prolonged antigen release. This has been completed by taking, as a building block, a nanostructured version of p30, a main structural immunogen from the African swine fever virus (ASFV). By challenging the system in both mice and pigs, we have observed unusually potent pro-inflammatory activity in porcine macrophages, and long-lasting humoral and cellular responses in vivo, which might overcome the need for an adjuvant. The robustness of both innate and adaptive responses tag, for the first time, these dynamic depot materials as a novel and valuable instrument with transversal applicability in immune stimulation and vaccinology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Structural Stabilization of Clinically Oriented Oligomeric Proteins During their Transit through Synthetic Secretory Amyloids

  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Parladé, Eloi|||0000-0001-5750-550X
  • Di Somma, Angela|||0000-0003-4916-7875
  • Livieri, Andrea|||0000-0002-0724-373X
  • Álamo, Patricia|||0000-0003-0510-5701
  • Mangues, Ramon|||0000-0003-2661-9525
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
Developing time-sustained drug delivery systems is a main goal in innovative medicines. Inspired by the architecture of secretory granules from the mammalian endocrine system it has generated non-toxic microscale amyloid materials through the coordination between divalent metals and poly-histidine stretches. Like their natural counterparts that keep the functionalities of the assembled protein, those synthetic structures release biologically active proteins during a slow self-disintegration process occurring in vitro and upon in vivo administration. Being these granules formed by a single pure protein species and therefore, chemically homogenous, they act as highly promising time-sustained drug delivery systems. Despite their enormous clinical potential, the nature of the clustering process and the quality of the released protein have been so far neglected issues. By using diverse polypeptide species and their protein-only oligomeric nanoscale versions as convenient models, a conformational rearrangement and a stabilization of the building blocks during their transit through the secretory granules, being the released material structurally distinguishable from the original source is proved here. This fact indicates a dynamic nature of secretory amyloids that act as conformational arrangers rather than as plain, inert protein-recruiting/protein-releasing granular depots.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Hybrid Micro-/Nanoprotein Platform Provides Endocrine-like and Extracellular Matrix-like Cell Delivery of Growth Factors

  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Tsimbouri, Penelope|||0000-0001-5124-7458
  • Jayawarna, Vineetha|||0000-0001-9865-3584
  • Rigou, Ioanna
  • Serna, Naroa|||0000-0001-5682-8198
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Salmeron-Sanchez, Manuel|||0000-0002-8112-2100
  • Vázquez, Esther|||0000-0003-1052-0424
  • Dalby, Matthew|||0000-0002-0528-3359
  • Villaverde, Antonio|||0000-0002-2615-4521
Protein materials are versatile tools in diverse biomedical fields. Among them, artificial secretory granules (SGs), mimicking those from the endocrine system, act as mechanically stable reservoirs for the sustained release of proteins as oligomeric functional nanoparticles. Only validated in oncology, the physicochemical properties of SGs, along with their combined drug-releasing and scaffolding abilities, make them suitable as smart topographies in regenerative medicine for the prolonged delivery of growth factors (GFs). Thus, considering the need for novel, safe, and cost-effective materials to present GFs, in this study, we aimed to biofabricate a protein platform combining both endocrine-like and extracellular matrix fibronectin-derived (ECM-FN) systems. This approach is based on the sustained delivery of a nanostructured histidine-tagged version of human fibroblast growth factor 2. The GF is presented onto polymeric surfaces, interacting with FN to spontaneously generate nanonetworks that absorb and present the GF in the solid state, to modulate mesenchymal stromal cell (MSC) behavior. The results show that SGs-based topographies trigger high rates of MSCs proliferation while preventing differentiation. While this could be useful in cell therapy manufacture demanding large numbers of unspecialized MSCs, it fully validates the hybrid platform as a convenient setup for the design of biologically active hybrid surfaces and in tissue engineering for the controlled manipulation of mammalian cell growth.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Lyophilization of biomimetic amyloids preserves their regulatable, endocrine-like functions for nanoparticle release

  • Favaro, Marianna T.P.|||0000-0003-2942-247X
  • López-Laguna, Hèctor|||0000-0001-5249-8304
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Sánchez, Julieta M.|||0000-0001-6676-5776
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
The secretory granules from the mammalian endocrine system are functional amyloids that act as dynamic depots to store and release protein hormones into the bloodstream. The controlled in vitro coordination between divalent cations and solvent-exposed histidine residues triggers reversible, cross-molecular interactions that result in granular protein aggregates with protein-leaking properties. While these synthetic particles are mechanically stable, they progressively disintegrate and release their protein building blocks, mimicking the performance of secretory granules. Envisaged as delivery systems for endocrine-like, time-sustained protein release, their clinical applicability should be supported by robust storage procedures, so far unset. Being lyophilization a desirable storage method for protein drugs, how this procedure could preserve the performance of clinically oriented functional amyloids is a neglected issue. We have here explored, tailored and validated lyophilization as an industrially and clinically friendly, fully scalable approach to the storage of functional amyloids aimed at secretion of protein-only nanoparticles. By doing so, protein-protein interactions in such materials have been characterized, and citrate identified as an efficient modulator of the temporal secretion profile, through which the sustainability of the leaking process can be finely regulated.